Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive Navigation
icon
News Archive Navigation Language
May 2022
-
Media ReleaseFDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1Sustained clinical benefit from Kymriah…
-
How Emily’s act of bravery inspired a wave of continued innovation
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life…
-
Boosting access to cancer care where it’s needed most
-
Featured NewsNovartis at ASCO and EHA 2022
-
Media ReleaseNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditionsPositive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these…
-
Media ReleaseNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancerLatest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
-
Media ReleaseNovartis provides update on production of radioligand therapy medicinesNovartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…
-
Media ReleaseNovartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host diseaseJakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2In clinical…
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patientsWith further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
-
Media ReleaseNovartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphomaKymriah offers patients in Europe with advanced follicular lymphoma a potentially definitive, single infusion CAR-T cell therapy with a remarkable safety profileApproval based on the Phase II ELARA…